William Blair Investment Management LLC Invests $16.02 Million in PROCEPT BioRobotics Corporation $PRCT

William Blair Investment Management LLC acquired a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the second quarter, HoldingsChannel reports. The firm acquired 709,484 shares of the company’s stock, valued at approximately $16,020,000.

Other hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after acquiring an additional 1,084 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the period. Center for Financial Planning Inc. bought a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at $40,000. Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the first quarter valued at $42,000. Finally, Essential Partners LLC lifted its holdings in shares of PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after purchasing an additional 1,980 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by insiders.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $21.68 on Friday. PROCEPT BioRobotics Corporation has a twelve month low of $16.67 and a twelve month high of $42.43. The firm has a fifty day simple moving average of $20.40 and a 200 day simple moving average of $24.20. The company has a market capitalization of $1.24 billion, a PE ratio of -11.18 and a beta of 0.89. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same period last year, the company posted ($0.35) EPS. The business’s revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

Wall Street Analyst Weigh In

Several analysts recently weighed in on PRCT shares. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $31.00 to $29.00 in a research note on Thursday, June 11th. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a research report on Wednesday, August 5th. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. UBS Group lowered PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research report on Tuesday, July 28th. Finally, Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.